Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 / 2 Study of INBRX-105 and INBRX-105 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

NCT03809624 is registered in ClinicalTrials.gov with Inhibrx Biosciences, Inc as lead sponsor.

NCT NCT03809624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03809624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 / 2 Study of INBRX-105 and INBRX-105 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Inhibrx Biosciences, Inc
Phase
Phase 1
Overall status
Terminated
Start date
January 30, 2019
Completion date
October 3, 2024
Enrollment
160 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal adenocarcinoma, gastric adenocarcinoma, head and neck squamous cell carcinoma, melanoma, metastatic solid tumors, nasopharyngeal carcinoma, non-small cell lung cancer, oropharyngeal carcinoma, renal cell carcinoma